Ultimovacs Announces Plenary Oral Presentation of Phase I Melanoma Trial Results at the 19th International Congress of the Society for Melanoma Research (SMR)
September 21, 2022 10:30 ET
|
Ultimovacs ASA
New clinical data from phase I trial UV1-103, combining UV1 with pembrolizumab in advanced melanoma will be presented Oslo, September 21 2022: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical...
Ultimovacs Announces Publication of Phase I Melanoma Trial Data in Journal of Translational Medicine
September 12, 2022 09:05 ET
|
Ultimovacs ASA
Comprehensive characterization of phase I UV1-checkpoint inhibitor combination trialClinical responses seen in patients with favored and less favored baseline characteristicsT cell activation observed...
Ultimovacs ASA: New share capital registered
September 09, 2022 02:53 ET
|
Ultimovacs ASA
Oslo, 9 September 2022, Ultimovacs ASA (the "Company") refers to the announcement published on 5 September 2022 regarding the issuance of new shares in connection with the Company's employee incentive...
Ultimovacs ASA: Mandatory notification of trade by primary insider
September 05, 2022 13:00 ET
|
Ultimovacs ASA
Oslo, 05 September 2022, Carlos de Sousa, Chief Executive Officer and primary insider in Ultimovacs ASA, has today bought 2,000 shares in the company at an average price of NOK 67.10 per share....
Ultimovacs ASA: Share capital increase related to exercise of options
September 05, 2022 10:30 ET
|
Ultimovacs ASA
Oslo, 05 September 2022, the Board of Directors of Ultimovacs ASA (the "Company") has resolved to increase the Company's share capital by NOK 4,400 through the issuance of 44,000 new shares, each with...
Ultimovacs Strengthens IP Portfolio with the United States Patent and Trademark Office (USPTO) Notice of Allowance on UV1 Method Patent
August 22, 2022 11:00 ET
|
Ultimovacs ASA
Will cover methods for eliciting T cell immune responseProtects US sales and marketing of UV1 Oslo, August 22, 2022: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in...
Ultimovacs ASA Reports Second Quarter 2022 Financial Results and Provides General Business Update
August 19, 2022 02:00 ET
|
Ultimovacs ASA
Oslo, August 19, 2022: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, announces its second quarter 2022 results today. The presentation by...
Ultimovacs Expands High Dose Cohort Size in TENDU Phase I Prostate Cancer Trial after Safety Review
August 18, 2022 02:00 ET
|
Ultimovacs ASA
The TENDU interim safety results from nine patients show no safety concernsTrial extended to enroll up to three additional patients at the highest dose levelTENDU designed to evaluate the...
Ultimovacs ASA: Invitation to second quarter 2022 results webcast presentation
August 12, 2022 02:00 ET
|
Ultimovacs ASA
Oslo, 12 August 2022: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, invites to a webcast presentation of its second quarter 2022 results...
Ultimovacs ASA: Mandatory notification of trade by primary insider
June 30, 2022 07:20 ET
|
Ultimovacs ASA
Oslo, 30 June 2022, a closely related party of Carlos de Sousa, Chief Executive Officer and primary insider in Ultimovacs ASA, has today bought 2,000 shares in the company at an average price of NOK...